Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLINI pre-operative nivolumab-based phase II trial in early breast cancer
NL-OMON54814Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab, relatlimab in breast cancer, triple-negative breast cancer (TNBC), sponsored by Netherlands Cancer Institute. Started Oct 2019; status: recruiting.
02
Drugs
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON54814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54814.